Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 4637-24-5 in 2025

Understanding 2,4-Dichlorobenzylamine (CAS No. 4637-24-5)

2,4-Dichlorobenzylamine (CAS No. 4637-24-5) is an important pharmaceutical intermediate used in the synthesis of various Active Pharmaceutical Ingredients (APIs). With its unique structure, featuring both chlorine and amine groups, 2,4-Dichlorobenzylamine plays a critical role in the synthesis of drugs, especially those targeting antimicrobial, anti-inflammatory, and anticancer applications.

As an intermediate, it facilitates complex chemical reactions that enable the production of high-quality drug formulations. Its versatility in pharmaceutical manufacturing makes it a key component in the development of effective treatments for various medical conditions.

Importance of 2,4-Dichlorobenzylamine in Drug Development

Antimicrobial Applications:

2,4-Dichlorobenzylamine is widely used in the synthesis of antimicrobial drugs. Its structure allows for the development of compounds with potent bactericidal or bacteriostatic properties, making it valuable in treating infections caused by resistant microorganisms.

Anti-inflammatory Properties:

Beyond its antimicrobial uses, this intermediate also contributes to the development of anti-inflammatory drugs. Its chemical properties allow for the creation of compounds that can regulate the immune system, reducing inflammation in conditions such as arthritis.

Oncology Drug Development:

The intermediate also plays a key role in producing anticancer agents. By serving as a precursor to active compounds used in cancer therapies, 2,4-Dichlorobenzylamine helps create drugs that are more effective and targeted, minimizing harmful side effects.

Regulatory Compliance:

As with all pharmaceutical intermediates, the production of 2,4-Dichlorobenzylamine must meet stringent regulatory standards, including Good Manufacturing Practices (GMP). This ensures that the final drug products are safe and effective for patients.

Scalability in Manufacturing:

2,4-Dichlorobenzylamine’s scalability in manufacturing processes allows pharmaceutical companies to produce large quantities of APIs while maintaining high-quality standards. This is crucial for meeting the increasing demand for essential medicines worldwide.

Top 10 Manufacturers of 2,4-Dichlorobenzylamine (CAS No. 4637-24-5)

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza is a leading global manufacturer of pharmaceutical intermediates, including 2,4-Dichlorobenzylamine. The company offers comprehensive services from research to commercial production, ensuring high-quality standards across all stages of drug development.

• Key Products: Custom synthesis, biopharmaceutical manufacturing, APIs for oncology and antimicrobial drugs.

2. BASF

• Location: Ludwigshafen, Germany

• Overview: BASF is one of the world’s largest chemical companies, providing high-quality pharmaceutical intermediates, including 2,4-Dichlorobenzylamine. Their advanced chemical manufacturing capabilities ensure that their products meet stringent regulatory requirements.

• Key Products: Pharmaceutical intermediates, custom synthesis, APIs for antimicrobial and anti-inflammatory drugs.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine is a major producer of pharmaceutical intermediates, including 2,4-Dichlorobenzylamine. Known for cost-effective solutions and high-quality standards, Eastfine is committed to meeting international regulatory guidelines to ensure the safety and efficacy of its products.

• Key Products: Pharmaceutical intermediates, fine chemicals for industrial applications, custom synthesis.

4. Evonik Industries

• Location: Essen, Germany

• Overview: Evonik is a key player in the pharmaceutical intermediate market, offering products like 2,4-Dichlorobenzylamine for various therapeutic applications, particularly antimicrobial and anti-inflammatory drug synthesis.

• Key Products: Custom synthesis, high-performance pharmaceutical intermediates, APIs for various therapeutic areas.

5. Mitsubishi Chemical Corporation

• Location: Tokyo, Japan

• Overview: Mitsubishi Chemical is a leading player in the chemical and pharmaceutical sectors, providing high-quality intermediates like 2,4-Dichlorobenzylamine. Their expertise in synthesis ensures efficient, high-purity production for pharmaceutical applications.

• Key Products: Pharmaceutical intermediates, high-purity APIs, and specialty chemicals.

6. Syngene International

• Location: Bangalore, India

• Overview: Syngene is a prominent contract research and manufacturing organization (CRMO) that provides custom synthesis services, including the production of 2,4-Dichlorobenzylamine. The company is known for its expertise in drug development and manufacturing.

• Key Products: Custom synthesis, pharmaceutical intermediates, API production for a variety of therapeutic applications.

7. Cambrex Corporation

• Location: East Rutherford, New Jersey, USA

• Overview: Cambrex is an expert in the development and manufacturing of small molecule APIs and pharmaceutical intermediates, including 2,4-Dichlorobenzylamine. Their services support the entire drug development lifecycle.

• Key Products: Small molecule APIs, custom synthesis, and regulatory support services.

8. Sandoz (Novartis Division)

• Location: Holzkirchen, Germany

• Overview: Sandoz, a division of Novartis, is a global leader in the generics market. The company produces 2,4-Dichlorobenzylamine and other intermediates essential for the production of generic drugs in areas like antimicrobials and anti-inflammatories.

• Key Products: Generic APIs, biosimilars, and pharmaceutical intermediates for various therapeutic areas.

9. Chempacific Corporation

• Location: USA (Operations based in North America)

• Overview: Chempacific specializes in the custom synthesis of pharmaceutical intermediates, including 2,4-Dichlorobenzylamine. Their focus on quality and flexibility makes them a trusted partner in drug development.

• Key Products: Custom synthesis, pharmaceutical intermediates, fine chemicals.

10. Mylan Pharmaceuticals (now part of Viatris)

• Location: Canonsburg, Pennsylvania, USA

• Overview: Mylan, now part of Viatris, is a major global generics producer. The company manufactures 2,4-Dichlorobenzylamine and other pharmaceutical intermediates used in the production of generics in therapeutic areas like oncology and infections.

• Key Products: Generic APIs, intermediates, contract manufacturing services.

Trends in the Pharmaceutical Intermediates Market

Rising Demand for Antimicrobial and Anti-inflammatory Drugs:

With the increasing global incidence of infections and chronic inflammatory diseases, the demand for intermediates like 2,4-Dichlorobenzylamine continues to rise. Pharmaceutical companies are focusing on developing novel antimicrobial and anti-inflammatory treatments to address these global health challenges.

Sustainability in Chemical Manufacturing:

As the pharmaceutical industry continues to prioritize sustainability, manufacturers are focusing on greener and more energy-efficient processes. Companies are adopting green chemistry approaches to reduce waste and environmental impact in the production of intermediates.

Technological Advancements in Synthesis:

Advances in chemical synthesis technologies, such as automated processes and continuous flow chemistry, are improving the efficiency and scalability of producing pharmaceutical intermediates like 2,4-Dichlorobenzylamine. These innovations help companies meet the increasing demand for high-quality intermediates.

Regulatory Compliance and Quality Assurance:

Stricter regulatory requirements are pushing manufacturers to invest in state-of-the-art facilities and quality control systems to ensure that intermediates like 2,4-Dichlorobenzylamine meet international safety and efficacy standards.

Conclusion

2,4-Dichlorobenzylamine (CAS No. 4637-24-5) is an essential pharmaceutical intermediate, playing a crucial role in the synthesis of antimicrobial, anti-inflammatory, and anticancer drugs. Leading manufacturers such as Lonza, BASF, Eastfine, and Mitsubishi Chemical continue to ensure the availability of this intermediate to meet the growing demand for specialized pharmaceuticals.

As the pharmaceutical industry advances, intermediates like 2,4-Dichlorobenzylamine will continue to play a central role in the development of novel, effective treatments, particularly in combating infectious diseases, chronic inflammation, and cancer.